**Systematic review and meta-analysis of interventions with dietary**

**supplements, including pre-, pro- and synbiotics, to reduce acute and late**

**gastrointestinal side effects in patients undergoing pelvic radiotherapy**

Benjamin Bartsch[1]#, Chee Kin Then[1]#, Elinor Harriss[2], Christiana Kartsonaki[3,4], Anne E.

Kiltie[1]*

[1]Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford,

Oxford, UK

[2]Bodleian Health Care Libraries, University of Oxford, Oxford, UK

[3]Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of

Population Health, University of Oxford, Oxford, UK

[4]Medical Research Council Population Health Research Unit (MRC PHRU) at the University of

Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, UK

#These authors contributed equally to this work.

*Corresponding author:

Professor Anne E Kiltie

Oxford Institute for Radiation Oncology

Department of Oncology, University of Oxford

Old Road Campus Research Building

Off Roosevelt Drive

Oxford OX3 7DQ

anne.kiltie@oncology.ox.ac.uk

+44 1865 617352

**ABSTRACT**

**Objective**: Pelvic radiotherapy (RT) often results in toxicity to the gastrointestinal tract and

clinical trials have demonstrated a potentially beneficial role of dietary supplements in

overcoming this problem, mainly acute effects. This systematic review and meta-analysis

were undertaken with the aim of evaluating the efficacy of several dietary supplement

interventions in preventing or alleviating symptoms of gastrointestinal toxicity in patients

undergoing RT for a range of common pelvic malignancies.

**Design**: The search protocol was prospectively submitted to PROSPERO at the University of

York. CENTRAL, MEDLINE, EMBASE, and ClinicalTrials.gov were searched up to June 2020 for

randomised controlled clinical trials. Interventions included four supplement categories:

biotics, amino acids, poly-unsaturated fatty acids and polyphenols. Efficacy was determined

with reference to outcomes based on symptoms of acute gastrointestinal toxicity, including

diarrhoea, nausea and vomiting.

**Results**: Twenty-three randomised controlled trials (1919 patients) were identified in this

review. Compared with placebo, probiotics, synbiotics and polyphenols were significantly

associated with a lower risk of diarrhoea. Biotic supplements also reduced the risk of

moderate to severe diarrhoea and the need for anti-diarrhoeal medication. In contrast,

amino acid supplements had no effect on acute symptoms. There was a non-significant

trend for reduction in nausea and mean bowel movements per day using dietary

supplements.

**Conclusions**: Biotic supplements, especially probiotics and synbiotics, reduce acute

symptoms of gastrointestinal toxicity in patients undergoing pelvic radiotherapy. More

randomised placebo-controlled studies with larger numbers of patients are needed to

define specific formulations for supplement interventions that will be of greatest benefit to patients.

**Summary box**

*1. What is already known about this subject?*

Clinical trials have indicated a potentially beneficial role of dietary supplements for the prevention and treatment of radiation-induced gastrointestinal symptoms.

*2. What are the new findings?*

In this systematic review, we found biotics and polyphenols can significantly reduce the risk of diarrhoea, while biotics were also associated with a lower incidence of moderate to severe diarrhoea and anti-diarrhoeal medication use. Among biotic supplements, both synbiotics and probiotics were found to be potentially beneficial in the prevention of diarrhoea.

*3. How might it impact on clinical practice in the foreseeable future?*

Cancer patients undergoing pelvic RT may benefit from taking biotic supplements for alleviation of gastrointestinal toxicity symptoms following pelvic radiation. More randomised controlled trials are required to determine the optimum formulations and combinations.

**Trial registration number**

The study protocol was published on the PROSPERO international prospective register of systematic reviews (registration number CRD42020183304).

1 **Keywords (up to 10):** amino acids, dietary supplements, meta-analysis, pelvic radiotherapy,

2 polyphenols, poly-unsaturated acids, prebiotics, probiotics, synbiotics, systematic review.

## 1 BACKGROUND

Radiotherapy is a major cancer treatment modality, used to treat approximately 50% of

patients[1]. Chemoradiation (concurrent delivery of systemic chemotherapy) is generally

preferred over radiotherapy alone for most pelvic malignancies, including tumours of the

lower gastrointestinal, gynaecological and urological (with the exception of prostate cancer)

tracts[2]. Over 200,000 patients in the US are treated with pelvic or abdominal radiotherapy

each year[3]. It is inevitable that normal gastrointestinal tissues are exposed to radiation

during pelvic radiotherapy[4], with approximately 80% of patients developing acute

symptoms of radiation-induced gastrointestinal toxicity[5]. However, despite their impact on

patients' quality of life, no prophylactic agents for the alleviation of gastrointestinal side-

effects from pelvic radiation have been approved to date[6].

The intestine is particularly radiosensitive due to the presence of rapidly replicating crypt

cells. Following irradiation, mucosal biopsies show evidence of extensive surface epithelial

atrophy, widespread disruption of absorptive and secretory activity and acute crypt

inflammation crypts[7]. Acute symptoms usually develop during or immediately after RT, and

typically improve within three months following RT[8]. The most common acute side effect is

diarrhoea, affecting up to 80% of all patients[9]. Other symptoms, such as abnormal stool

output, vomiting and gastrointestinal discomfort are also very common. Late symptoms

include GI bleeding, fistula, stricture and colostomy[10].

Use of a dietary supplement is aimed at boosting daily intake of specific nutrients, to much

higher levels than obtained from the diet, to alleviate symptoms of gastrointestinal toxicity.

Such dietary supplements include biotics, amino acids, poly-unsaturated fatty acids (PUFAs)

and polyphenols. Probiotics, mainly of the *Lactobacillus* and *Bifidobacteria* genera, are live

microorganisms thought to produce health benefits following passage to the intestine[11].

Prebiotics are soluble or non-soluble dietary fibres, that pass undigested through the upper

gastrointestinal tract and are metabolised by bacteria in the colon, thus enhancing gut

microbiota beneficial to the host's health[12]. Examples of prebiotics include inulin, fructo-

oligosaccharide, psyllium husk and alpha-amylase resistant starch. The use of synbiotics

refers to administration of a combination of prebiotics and probiotics; the presence of the

prebiotic enhances survival of the probiotics in the lower gastrointestinal tract.

Administration of probiotics, prebiotics and synbiotics can alter the gut microbiota and

production of key metabolites, resulting in reduced symptoms of disease and promotion of

well-being[13 14].

Amino acids, poly-unsaturated acids (PUFAs) and polyphenolic compounds have also been

employed in supplement intervention strategies in pelvic RT. Dietary PUFAs comprise a

number of molecules. Anti-inflammatory effects of the omega-6 PUFA conjugated linolenic

acids (CLA) are seen in inflammatory bowel disease[15]. Furthermore, the omega-3 fatty acids,

docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may be capable of boosting

cancer cell sensitivity to drugs[16]. Glutamine is the most abundant amino acid with important

roles in support of mucosal growth and function. Evidence from animal studies confirms

that dietary glutamine supplementation can protect the small intestinal epithelium from

radiation damage[17]. Polyphenolic compounds extracted from plants, such as flavanols,

flavandiols, epigallocatchin and genistein, can also suppress or alleviate radiation-induced

intestinal injury. Oral administration of curcumin reversed morphological damage caused by

radiation treatment to rat ileal villi[18]. Genistein and other isoflavones extracted from soy

bean are similarly implicated in anti-inflammatory responses, protecting irradiated mouse

jejunum from adverse changes and attenuating tumour growth[19].

This review tests the hypothesis that administration of oral dietary supplements for cancer

patients receiving pelvic radiotherapy may trigger changes in the lower gastrointestinal tract

which lead to a reduction in gastrointestinal toxicity. We conducted a systematic review and

meta-analysis of randomised controlled trials (RCTs), with the aim of determining whether

dietary interventions using supplements can alleviate symptoms of gastrointestinal toxicity

in pelvic RT patients, including diarrhoea, nausea, vomiting, flatulence/bloating and bowel

movement frequency.

**METHODS**

**Search strategy and study selection**

The following electronic databases were searched from inception to the search date

(19/06/2020) for relevant literature: Cochrane CENTRAL, Ovid Medline, Ovid Embase, and

ClinicalTrials.gov. The search strategies included both medical subject heading and free text

terms to retrieve relevant RCTs and non-randomised studies about the gastrointestinal side

effects in cancer patients undergoing pelvic radiotherapy, limiting to studies in humans only.

The full set of search strategies is available in Appendix 1 to 3, and inclusion and exclusion

criteria are available in the PROSPERO registration[20]. Relevant articles were identified on

PubMed. Handsearching of meta-analyses, systematic reviews and papers identified studies

not indexed in the electronic databases used for this review. All titles and abstracts

retrieved by electronic searches were downloaded and duplications removed using EndNote

reference management software. Full-text copies of short-listed titles were obtained to

determine if they met the eligibility criteria. Multiple reports of the same study data were

eliminated, thus any original data were only included once.

**Data extraction**

Systematic data collection from included studies was conducted using a data collection form

designed specifically for this review. It included the following information (where available)

for each dataset: publication year, study design, participants (number, age distribution,

gender distribution, details of malignancy, details relevant to inclusion and exclusion

criteria), current cancer treatment (duration, fractionation and dose of RT and details of any

chemotherapy), intervention (type of supplement, route of intervention, formulation, dose,

timing with respect to RT, length of treatment and follow-up) and measured outcomes

(diarrhoea incidence and severity and details of other GI symptoms recorded as toxicity

scores, patient-reported outcome measure scores, questionnaires or interview scores).

Details of included studies were summarised according to the PICO model[21]. Where raw

data were unavailable, EndNote was used to facilitate extraction of data from charts and

graphs of the included studies[22]. Details of outcomes included time points at which they

were reported by study authors.

**Outcome assessment**

Different measures of treatment effects were used for dichotomous and continuous

outcomes, namely, risk ratio (RR) for dichotomous outcomes and the mean difference (MD)

between the intervention and control arms for continuous outcomes.

Standardised mean difference (SMD) was used to compare to compare results from studies

that reported the same outcomes measured on different scales.

**Study quality**

Risk of bias assessment was carried out for all studies that met the inclusion criteria, using

the Cochrane Risk of Bias 2 (ROB2) tool[23]. The ROB2 framework investigates five domains in

a study, namely, the biases arising from the randomisation process, due to deviations from

intended interventions, due to missing outcome data, in measurement of the outcome and

in the selection of the reported result, with three levels of risk of bias, namely, low risk,

some concerns and high risk. The risk of bias across the five domains was then used to

derive an overall risk score. Judgements were based on assessment of statements in the

included studies relevant to study design. In some instances, key information was

incomplete, unclear or omitted from published protocols.

**Assessment of heterogeneity and publication bias**

To assess the heterogeneity, we used a chi-squared test and $I^2$ [24] [25]. P values less than 0.1

were considered as evidence of heterogeneity. $I^2$ values between 0% to 40% indicated

'might not be important', 30% to 60% indicated 'may represent moderate heterogeneity',

50% to 90% indicated 'may represent substantial heterogeneity' and 75% to 100% indicated

'considerable heterogeneity' based on the Cochrane handbook[26]. Tau-squared is the

estimated standard deviation of underlying effects across studies. Begg's funnel plots were

used to visually assess asymmetry potentially due to publication bias.

**Data synthesis and statistical analysis**

Meta-analyses were performed to measure the effect of dietary supplements on an

outcome, in instances where there were three or more studies that reported the same

outcome. All analyses were conducted using RevMan 5.4 and R version 4.0.2 with package

'meta'[27] [28] . For dichotomous outcomes, risk ratios (RR) were estimated and were meta-

analysed using a random effects model using the Mantel-Haenszel (M-H) method[29]. For

continuous outcomes, mean differences (MD) were estimated and were pooled using a

random effects model with the inverse variance (IV) method. 95% confidence intervals (CI)

for all estimates were calculated. For each outcome, the studies selected for quantitative

analysis were divided into subgroups, based on the class of intervention. Studies that met

inclusion criteria investigated the effect of one of the following classes: biotics, amino acids,

PUFAs and polyphenols. Subgroup analysis by subclass of biotic intervention (prebiotic,

probiotic and synbiotic) was also performed. Meta-regression by mean age, proportion of

male participants and sample size was used to assess whether the effects of interventions

on incidence of diarrhoea varied by these study characteristics.

**Patient and public involvement**

There was no patient or public involvement in the design or conduct of this study.

**RESULTS**

The search of the four primary databases identified 23,542 titles published between 1946

and June 2020 (search process summarised in Figure 1). After 5,825 duplications were

removed, a total of 17,717 entries remained. These studies were manually reviewed by title

and abstract and 17 met the inclusion criteria. Six further studies were identified from

manual searches of the reference sections of research articles. Finally, 23 studies met the

inclusion criteria and could be used for quantitative analysis. The effects of interventions on

incidence of diarrhoea did not vary by mean age, proportion of male participants or sample

size (Figure S1). Results of the overall and individual risk of bias assessments for each of the

five domains are presented in Figure S2. Fourteen studies had low risk, three studies had

moderate risk, and six studies had high overall risk of bias.

**Included studies and characteristics of included studies**

In total 23 studies involving a total of 1,919 patients met the inclusion criteria and for each

outcome, they were grouped by intervention category. These studies were all randomised

controlled trials and their characteristics are shown in the Table 1. All included studies

investigated the effect of dietary supplements on <u>acute</u> symptoms of gastrointestinal

toxicity. However, the individual trials differed widely in the symptoms and outcomes they

reported. In total, the trials included in the review reported ten different relevant

symptoms. For each symptom, data could be expressed according to the following three

outcomes: number of events, severity and time, as shown in Table S1.

**Efficacy of dietary supplements in preventing diarrhoea**

The meta-analysis comprising 1,625 patients showed that dietary supplements reduced the

risk of diarrhoea (Figure 2). The pooled risk ratio (RR) was 0.79 (95% CI: 0.66 to 0.94;

P=0.007) and there was significant heterogeneity amongst the studies ($I^2$=73%; P<0.001).

The funnel plot for this meta-analysis (Figure 3) was largely symmetrical, implying only mild

publication bias in the references included. There was no evidence that heterogeneity was

due to mean age or sex of participants or sample size of the studies. Meta-analyses were

then carried out for biotic, amino acid, poly-unsaturated fatty acid and polyphenol

interventions.

*Efficacy of biotics in preventing diarrhoea*

Biotic interventions significantly reduced the risk of diarrhoea with a RR of 0.66 (95% CI:

0.51 to 0.86; P=0.002) (Figure 2). All studies, except Giralt *et al*[30], had a RR of less than 1,

suggesting the protective role of biotics against diarrhoea. The heterogeneity, $I^2$, among

these studies was 76% (P<0.001), so further analysis of the subclasses of probiotics and

synbiotics was performed (Figure 4). The risk ratio for synbiotics (RR=0.45; 95% CI: 0.28 to

0.73) was lower than for probiotics (RR=0.71; 95% CI: 0.52 to 0.99). There was little

heterogeneity among studies on synbiotics ($I^2$=0%; P=0.50).

*Efficacy of amino acids in preventing diarrhoea*

Amino acid interventions were not associated with risk of diarrhoea with a RR of 1.05 (95%

CI=0.86 to 1.29; P=0.65, Figure 2). Five studies which included 348 patients were used to

compare the incidence of diarrhoea between intervention and control groups. We found

that four studies had consistent results of RR which were close to 1, but only Vidal-

Cassariego *et al* reported a high RR of 2.75. There was high heterogeneity among studies

($I^2$=62%, P=0.03).

*Efficacy of poly-unsaturated fatty acids in preventing diarrhoea*

There was only one study in the category of poly-unsaturated fatty acids reporting the

outcome incidence of diarrhoea (Figure 2). This was a relatively small randomised controlled

trial with only 40 patients. This study had a RR of 0.63 (95% CI=0.25 to 1.58; P=0.32).

*Efficacy of polyphenol in preventing diarrhoea*

Two studies compared polyphenols and placebo among 64 patients (Figure 2). Both showed

that the intervention was associated with lower incidence of diarrhoea. The overall RR was

0.30 (95% CI=0.13 to 0.70, P=0.005). There was no evidence of heterogeneity between

these two studies ($I^2$ = 0%, P=0.86).

**Efficacy of dietary supplements in preventing moderate to severe diarrhoea**

Efficacy of dietary supplements was assessed against moderate to severe diarrhoea, with the incidence of moderate to severe diarrhoea defined as the incidence of grade 2 or higher diarrhoea, based on Common Technology Criteria for Adverse Events (CTCAE)[31] (Figure 5). Dietary supplements were associated with a lower risk of moderate to severe diarrhoea (RR=0.68; 95% CI: 0.48 to 0.98; P=0.04). There was high heterogeneity among studies ($I^2$=65%, P=0.009). The subgroup analysis suggested that the association was mainly driven by biotic interventions for which the RR was 0.49 (95% CI: 0.36 to 0.67; P<0.001), but not amino acids (RR=1.05; 95% CI: 0.82 to 1.34; P=0.70).

**Efficacy of dietary supplements in preventing the use of anti-diarrhoeal medication**

Anti-diarrhoeal medication, such as loperamide, is often employed for patients who experience diarrhoea during or after radiotherapy. Therefore, we measured the effect of dietary supplements against the incidence of anti-diarrhoeal medication use (Figure 6), and found that dietary supplements were associated with lower risk of anti-diarrhoeal medication use in patients (RR=0.67; 95% CI: 0.47 to 0.96; P=0.03) and there was high heterogeneity among studies ($I^2$=62%, P=0.01). For biotic interventions, the RR was 0.64 (95%CI: 0.44 to 0.92) and heterogeneity was intermediate ($I^2$=45%; P=0.11).

**Effects of dietary supplements on nausea, vomiting, flatulence/bloating and bowel**

**movement frequency**

Table 2 lists the results of meta-analysis of the other outcomes, including nausea, vomiting,

flatulence/bloating and bowel movement frequency. Dietary supplements tended to

decrease the risk of nausea (RR=0.74; 95% CI: 0.36 to 1.50; P=0.40) and the mean number of

bowel movements per day (mean difference=-3.88; 95% CI: -10.29 to 2.52; P<0.001). The

results also showed that the interventions had no effect on vomiting and flatulence/bloating

with relative risks of 0.99 (95% CI: 0.79 to 1.25, P=0.95) and 1.12 (95% CI: 0.59 to 2.12;

P=0.72) respectively.

# DISCUSSION

In this review, 23 randomised controlled trials met inclusion criteria for quantitative analysis. Risk of bias assessment was conducted for each of these studies. Meta-analyses were carried out for seven of these outcomes. These showed that dietary supplements are effective in reducing the risk of diarrhoea, experiencing moderate to severe diarrhoea and anti-diarrhoeal medication use. Subgroup analysis showed that biotic supplements and polyphenols were effective in reducing the risk of these outcomes, but amino acids were ineffective. Among the subclasses of biotic interventions, both probiotic and synbiotic supplements were shown to be effective in reducing the risk of diarrhoea. Taken together, these results indicate that biotic supplements can reduce the risk of acute diarrhoea and the severity of diarrhoea in patients undergoing pelvic radiotherapy.

There are important differences within and among the intervention groups regarding the administration of the dietary supplements. This includes amount, timing and composition of the supplement. Biotics represent a diverse range of interventions, including prebiotic, probiotic and synbiotic interventions. Probiotic and synbiotic interventions can be administered as a single strain/species of bacteria or a mixture of different strains/species. Since little is known their interactions with the gut microbiota[32], it is difficult to directly compare the included trials. For the included studies, dose and choice of strains were likely based on empirical observations of perceived benefits to lower gastrointestinal tract health in other settings. For example, there is a history of treating inflammatory bowel disease using bacteria with well-established dosage and strain parameters. Even within a bacterial genus, biological activities are strain-specific. For example, *Lactobacillus casei* has a different functional repertoire to other *Lactobacillus* strains[33], making a comparison with studies using

*L. acidophilus* or *L. rhamnosus* difficult. This hampers interpretation of results of using a

mixture of different strains. Delia *et al* used a cocktail of eight strains, including four strains

of *Lactobacilli*, three strains of *Bifidobacterium*, and *Streptococcus salivarius*[34].

Polyphenol interventions are complicated in several respects. Firstly, they are administered

as plant extracts, rather than a single purified active agent. Secondly, polyphenols are subject

to chemical modification in the small intestine[35] and limited bioavailability can be a problem.

Conversely, the amino acid interventions in this review are all based on pure glutamine, with

a comparatively narrow range of doses administered (8g - 45g/day). This standardisation

should enable high levels of comparability between trials in this intervention category. The

studies investigating PUFA interventions were based on omega-6 CLA or omega-3 fatty acids

supplements. Only two studies in this intervention category met inclusion criteria, as many

such trials investigate symptoms of radiation-induced cachexia, including weight and skeletal

muscle loss[36].

Our study is the only reported meta-analysis that investigates the efficacy of four different

classes of dietary supplements on acute symptoms of gastrointestinal toxicity. Most previous

meta-analyses investigated only a single class of dietary supplement. This review includes

more studies (23) and patients (1,919) than other published reviews, increasing confidence

in the quantitative analysis. Several meta-analyses have been conducted for probiotic and

synbiotic supplements over the last decade, but the category of prebiotics has not yet been

analysed. Therefore, the inclusion of prebiotics in this review is another key distinguishing

feature. The previous meta-analyses investigating the effects of biotic supplements on acute

symptoms of gastrointestinal toxicity are listed in Table S2. Overall, the trials included in each

meta-analysis are largely identical. Where different selections were made, this is mainly due

to variations in search strategy and the statistical methods used. A Cochrane systematic

review has also investigated the efficacy of interventions, including radiotherapy techniques

and pharmacological and non-pharmacological interventions, on acute and late adverse

gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers[4]. Compared to their

study of non-pharmacological interventions, including dietary interventions, probiotics,

glutamine, counselling, and protein supplements, our focused approach showed that the

beneficial effects mainly came from the probiotics and synbiotics. Also, the focus of the

Cochrane review was on prevention, rather than treatment, of acute symptoms of

gastrointestinal toxicity, an important difference to our review. Additionally, their search was

only updated to November 2017; our search to June 2020 included three more recent studies

of biotic supplements (224 patients) and one study focusing on PUFA supplements (40

patients). Currently, there are no published meta-analyses that investigate the effect of PUFA

or polyphenol supplements on acute symptoms of gastrointestinal toxicity, and two included

studies of polyphenols suggested that they are beneficial in preventing diarrhoea. One

analysis investigating amino acid supplements (glutamine) was identified[37] but rejected

because of different endpoints used. The authors included 13 RCTs investigating acute

symptoms of radiation enteritis, with the following outcomes, abdominal cramping, blood in

bowel movement and tenesmus. The researchers found that amino acid supplements were

not effective in improving symptoms. This finding is consistent with the result of this review

that amino acid supplements are ineffective in improving acute symptoms of gastrointestinal

toxicity.

A strength of our meta-analysis is that the data relate to patients undergoing pelvic

radiotherapy. They are not derived from cell lines or animal model systems. A further strength

is that the trials are based on direct measurements of the symptoms of gastrointestinal

toxicity, rather than less direct measures of effect, such as immunological, biochemical or

histological markers. Therefore, the findings of this review can be directly applied to clinical

practice. However, patient-related factors of low numbers (<40) of participants in 26% of

included studies represent a weakness in the statistical treatment of data sets, resulting in

wider confidence intervals. Most data were derived from single-centre trials, thus limiting the

ability to recruit larger numbers of patients. Furthermore, the baseline heterogeneity of the

patient cohorts is high, as it is not possible to subdivide patients into meaningfully

representative sub-groups in terms of age, sex, lifestyle-related factors, co-morbidities and

type of cancer.

The underlying protective effects of dietary supplements against GI toxicities may be

mediated as shown in Figure 7. A direct effect on the intestinal immune environment

following intake of specific dietary agents may lead to anti-inflammatory changes that

alleviate gastrointestinal toxicity. There may also be an indirect effect, whereby the above

immunomodulatory actions are developed in response to changes in the gut microbiota and

their metabolites, particularly SCFAs.

In terms of probiotics, these can act in three beneficial ways. Firstly, their presence may

down-regulate epithelial apoptosis and reduce inflammatory activity of the digestive tract,

possibly involving intact signalling of TLR-2, MyD88 and COX-2[38]. Secondly, in the presence of

dietary fibre, probiotics produce the SCFA butyrate. Butyrate is implicated in the reduction of

mucosal inflammation and promotion of epithelial repair following injury. Thirdly, probiotics

may provide resistance against infection of the damaged mucosa by pathogens. The scientific

consensus is that two classes of mechanisms are involved[39], namely direct and indirect effects.

Direct effects involve competition between commensal and pathogenic bacteria for the same

ecological niche. This competition comprises competition for nutrients and production of

antimicrobial peptides and toxins[40]. By contrast, indirect effects involve improvement in

intestinal mucosal function and stimulation of the innate and adaptive immune systems by

commensal bacteria[41].

In our meta-analysis, two studies demonstrated that polyphenols reduced the risk of

diarrhoea with an overall RR of 0.30 (95% CI=0.13 to 0.70; P=0.005). In line with this finding,

polyphenols have anti-oxidant and anti-inflammatory effects in human[42]. As anti-oxidants,

polyphenols reduce oxidative damage by preventing the formation of reactive oxygen species

(ROS) and reactive nitrogen species (RNS), and by preventing the generation of these

species[43]. In this way, polyphenols protect tissues against oxidative stress from ROS and RNS

which are both products of radiotherapy[44]. It is important to acknowledge that polyphenols

also have other important properties, such as anti-histamine, anti-bacterial and anti-viral

effects. We can speculate that the mechanisms underlying these effects are similar to those

responsible for the anti-oxidant and anti-inflammatory effects, with possibly overlap.

This review aimed to investigate the effect of dietary supplements on acute and late

symptoms, but there were no studies reporting on late side effects among included studies.

Chronic symptoms of gastrointestinal toxicity typically emerge a few months to years

following irradiation and occur in most of the intestinal compartments[45]. The prevalence of

chronic symptoms is reported to be between 5 and 15%[46] and can result in potentially fatal

complications such as fistulation, sepsis and perforation of the colon[4,35]. Due to

improvements in pelvic cancer treatment, the number of cancer survivors is increasing.

Consequently, more patients are potentially at risk of chronic symptoms of gastrointestinal

toxicity. However, improvements in pelvic cancer treatment, such as the use of image guided

radiotherapy, have in turn resulted in a decrease in chronic radiation effects[47]. The

pathophysiology of chronic effects is more complicated than acute effects[48]. Evidence from

clinical studies suggests that acute and chronic effects are linked, with the risk of developing

late effects greater in patients that have developed acute effects (consequential late

effects)[49-51]. Consistent with this finding, a systematic review that investigated the

relationship between acute and late gastrointestinal toxicity after RT for prostate cancer

concluded that acute GI toxicity may be predictive of high risk of developing late effects[51].

Taken together, the evidence suggests that dietary supplements could ameliorate chronic

symptoms of gastrointestinal toxicity in two ways: directly, by minimising the

pathophysiology underlying chronic effects, including differentiation of mitotic fibroblasts

into post-mitotic fibroblasts, and indirectly, by reducing the magnitude of acute symptoms

and the resulting consequential late effects.

## CONCLUSION

Findings from our systematic review and meta-analysis suggest that biotic supplements, specifically probiotics and synbiotics, are effective in reducing the risk and severity of acute symptoms of gastrointestinal toxicity caused by pelvic radiotherapy. The data also broadly confirm that they are safe to use.

**DECLARATIONS**

**Acknowledgements**

N/A

**Funding**

This work was funded by Cancer Research UK Programme grant C5255/A23755. The funding

body had no role in the design of the study, collection, analysis, interpretation of data or in

writing the manuscript.

**Authors' contributions**

BB performed the title/abstract selection, data extraction, interpretation of the data, risk of

bias assessment and drafted the manuscript. CKT reviewed the title/abstract selection,

performed the analysis, and did the risk of bias assessment. EH ran the search strategy

through the databases and clinical trials registry. CK performed meta-regression and

reviewed the results of statistical analysis. AEK conceived the study, supervised the work,

and revised the manuscript. All authors critically reviewed the manuscript and approved the

final version.

**Competing interests**

The authors declare that they have no competing interests.

**Ethics Approval and Consent to Participate**

N/A

# REFERENCES

1. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. *Nat Rev Cancer* 2011;11(4):239-53.

2. Morris KA, Haboubi NY. Pelvic radiation therapy: Between delight and disaster. *World J Gastrointest Surg* 2015;7(11):279-88.

3. Frazzoni L, La Marca M, Guido A, et al. Pelvic radiation disease: Updates on treatment options. *World J Clin Oncol* 2015;6(6):272-80.

4. Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. *Cochrane Database Syst Rev* 2018;1:CD012529.

5. Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? *Gut* 2005;54(8):1051-4.

6. Gibson RJ, Keefe DM, Lalla RV, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. *Support Care Cancer* 2013;21(1):313-26.

7. Larsen A, Bjorge B, Klementsen B, et al. Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. *Acta Oncol* 2007;46(5):639-50.

8. Stacey R, Green JT. Radiation-induced small bowel disease: latest developments and clinical guidance. *Ther Adv Chronic Dis* 2014;5(1):15-29.

9. Visich KL, Yeo TP. The prophylactic use of probiotics in the prevention of radiation therapy-induced diarrhea. *Clin J Oncol Nurs* 2010;4(14):467-73.

10. Kim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. *Eur Urol* 2011;60(5):908-16.

11. Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. *Int J Environ Res Public Health* 2014;11(5):4745-67.

12. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* 2014;11(8):506-14.

13. Pineiro M, Asp NG, Reid G, et al. FAO Technical meeting on prebiotics. *J Clin Gastroenterol* 2008;42 Suppl 3 Pt 2:S156-9.

14. Dinan TG, Cryan JF. The impact of gut microbiota on brain and behaviour: implications for psychiatry. *Curr Opin Clin Nutr Metab Care* 2015;18(6):552-8.

15. Bassaganya-Riera J, Hontecillas R. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. *Curr Opin Clin Nutr Metab Care* 2010;13(5):569-73.

16. Hajjaji N, Bougnoux P. Selective sensitization of tumors to chemotherapy by marine-derived lipids: a review. *Cancer Treat Rev* 2013;39(5):473-88.

17. Jensen JC, Schaefer R, Nwokedi E, et al. Prevention of chronic radiation enteropathy by dietary glutamine. *Ann Surg Oncol* 1994;1(2):157-63.

18. Akpolat M, Kanter M, Uzal MC. Protective effects of curcumin against gamma radiation-induced ileal mucosal damage. *Arch Toxicol* 2009;83(6):609-17.

19. Son TG, Gong EJ, Bae MJ, et al. Protective effect of genistein on radiation-induced intestinal injury in tumor bearing mice. *BMC Complement Altern Med* 2013;13:103.

20. Kiltie A, Bartsch B, Then CK, et al. Systematic review and meta-analysis of interventions with dietary supplements, including pre-, pro- and synbiotics, to reduce acute and late gastrointestinal side effects in patients undergoing pelvic radiotherapy: PROSPERO; 2020 [Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=183304.

21. Richardson WS, Wilson MC, Nishikawa J, et al. The well-built clinical question: a key to evidence-based decisions. *ACP J Club* 1995;123(3):A12-3.

22. EndNote [program]. EndNote X9 version. Philadelphia, PA: Clarivate, 2013.

23. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.

24. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557-60.

25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539-58.

26. JPT H, J T, J C, et al. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane, 2019.

27. Review Manager (RevMan) [program]. Version 5.4 version. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.

28. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health* 2019;22(4):153-60.

29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959;22(4):719-48.

30. Giralt J, Regadera JP, Verges R, et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: Results from multicenter, randomized, placebo-controlled nutritional trial. *Int J Radiat Oncol* 2008;71(4):1213-19.

31. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In: SERVICES USDOHAH, ed.: National Cancer Institute, National Institutes of Health, 2017.

32. Coyte KZ, Schluter J, Foster KR. The ecology of the microbiome: Networks, competition, and stability. *Science* 2015;350(6261):663-6.

33. Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. *Antonie Van Leeuwenhoek* 1996;70(2-4):347-58.

34. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. *World J Gastroentero* 2007;13(6):912-15.

35. Marin L, Miguelez EM, Villar CJ, et al. Bioavailability of Dietary Polyphenols and Gut Microbiota Metabolism: Antimicrobial Properties. *Biomed Res Int* 2015;2015

36. Aredes MA, da Camara AO, de Paula NS, et al. Efficacy of omega-3 supplementation on nutritional status, skeletal muscle, and chemoradiotherapy toxicity in cervical cancer patients: A randomized, triple-blind, clinical trial conducted in a middle-income country. *Nutrition* 2019;67-68:110528.

37. Cao DD, Xu HL, Xu M, et al. Therapeutic role of glutamine in management of radiation enteritis: a meta-analysis of 13 randomized controlled trials. *Oncotarget* 2017;8(18):30595-605.

38. Ciorba MA, Riehl TE, Rao MS, et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. *Gut* 2012;61(6):829-38.

39. Sassone-Corsi M, Raffatellu M. No Vacancy: How Beneficial Microbes Cooperate with Immunity To Provide Colonization Resistance to Pathogens. *J Immunol* 2015;194(9):4081-87.

40. Kim S, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. *Immunol Rev* 2017;279(1):90-105.

41. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. *Nat Rev Immunol* 2013;13(11):790-801.

42. Ogawa K, Hirose S, Nagaoka S, et al. Interaction between Tea Polyphenols and Bile Acid Inhibits Micellar Cholesterol Solubility. *J Agric Food Chem* 2016;64(1):204-9.

43. Hussain T, Tan B, Yin Y, et al. Oxidative Stress and Inflammation: What Polyphenols Can Do for Us? *Oxid Med Cell Longev* 2016;2016:7432797.

44. Gupta SC, Hevia D, Patchva S, et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. *Antioxid Redox Signal* 2012;16(11):1295-322.

45. Shah V, Lyford G, Gores G, et al. Nitric oxide in gastrointestinal health and disease. *Gastroenterology* 2004;126(3):903-13.

46. Olcina MM, Giaccia AJ. Reducing radiation-induced gastrointestinal toxicity - the role of the PHD/HIF axis. *Journal of Clinical Investigation* 2016;126(10):3708-15.

47. Murray J, Griffin C, Gulliford S, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. *Radiother Oncol* 2020;142:62-71.

48. Dorr W. Radiobiology of tissue reactions. *Ann ICRP* 2015;44(1 Suppl):58-68.

49. Bourne RG, Kearsley JH, Grove WD, et al. The Relationship between Early and Late Gastrointestinal Complications of Radiation-Therapy for Carcinoma of the Cervix. *Int J Radiat Oncol* 1983;9(10):1445-50.

50. Wang CJ, Leung SW, Chen HC, et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: Evidence suggestive of consequential late effect (CQLE). *Int J Radiat Oncol* 1998;40(1):85-91.

51. Peach MS, Showalter TN, Ohri N. Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer. *Prostate Cancer* 2015;2015

52. Sasidharan BK, Ramadass B, Viswanathan PN, et al. A phase 2 randomized controlled trial of oral resistant starch supplements in the prevention of acute radiation proctitis in patients treated for cervical cancer. *J Cancer Res Ther* 2019;15(6):1383-91.

53. Linn YH, Thu KK, Win NHH. Effect of Probiotics for the Prevention of Acute Radiation-Induced Diarrhoea Among Cervical Cancer Patients: a Randomized Double-Blind Placebo-Controlled Study. *Probiotics Antimicro* 2019;11(2):638-47.

54. de Loera-Rodriguez LH, Ortiz GG, Rivero-Moragrega P, et al. Effect of symbiotic supplementation on fecal calprotectin levels and lactic acid bacteria, Bifidobacteria, Escherichia coli and Salmonella DNA in patients with cervical cancer. *Nutr Hosp* 2018;35(6):1394-400.

55. Mansouri-Tehrani HS, Khorasgani MR, Roayaei M. Effects of Probiotics with or without Honey on Radiation-induced Diarrhea. *International Journal of Radiation Research* 2016;14(3):205-13.

56. Garcia-Peris P, Velasco C, Lozano MA, et al. Effect of a mixture of inulin and fructo-oligosaccharide on lactobacillus and bifidobacterium intestinal microbiota of patients receiving radiotherapy; a randomised, double-blind, placebo-controlled trial. *Nutr Hosp* 2012;27(6):1908-15.

57. Itoh Y, Mizuno M, Ikeda M, et al. A Randomized, Double-Blind Pilot Trial of Hydrolyzed Rice Bran versus Placebo for Radioprotective Effect on Acute Gastroenteritis Secondary to Chemoradiotherapy in Patients with Cervical Cancer. *Evid-Based Compl Alt* 2015

58. Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: Impact of probiotics on diarrhea in patients treated with pelvic radiation. *Clin Nutr* 2014;33(5):761-67.

59. Chitapanarux I, Chitapanarux T, Traisathit P, et al. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. *Radiat Oncol* 2010;5

60. Castro MG, Sanchez PX, Glasberg J, et al. Effects of probiotic in prevention of radiation-induced diarrhea. *Clinical Nutrition Supplements* 2009;4(2):72-73.

61. Urbancsek H, Kazar T, Mezes I, et al. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus (R) in patients with radiation-induced diarrhoea. *Eur J Gastroen Hepat* 2001;13(4):391-96.

62. Murphy J, Stacey D, Crook J, et al. Testing control of radiation-induced diarrhea with a psyllium bulking agent: a pilot study. *Can Oncol Nurs J* 2000;10(3):96-100.

63. Salminen E, Elomaa I, Minkkinen J, et al. Preservation of Intestinal Integrity during Radiotherapy Using Live Lactobacillus-Acidophilus Cultures. *Clin Radiol* 1988;39(4):435-37.

64. Vidal-Casariego A, Calleja-Fernandez A, de Urbina-Gonzalez JJ, et al. Efficacy of glutamine in the prevention of acute radiation enteritis: a randomized controlled trial. *JPEN J Parenter Enteral Nutr* 2014;38(2):205-13.

65. Manir K, Kallol B, Gaurav K, et al. Role of glutamine versus placebo in prevention of acute gastrointestinal toxicity in pelvic radiotherapy: A randomized control study. . *Clinical Cancer Investigation Journal* 2014;3(6):508-13.

66. Kucuktulu E, Guner A, Kahraman I, et al. The protective effects of glutamine on radiation-induced diarrhea. *Supportive Care in Cancer* 2013;21(4):1071-75.

67. Kozjek NR, Kompan L, Soeters P, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: A randomised double blinded, placebo controlled pilot study. *Clin Nutr* 2011;30(5):567-70.

68. Kozelsky TF, Meyers GE, Sloan JA, et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. *J Clin Oncol* 2003;21(9):1669-74.

69. Faramarzi E, Mahdavi R, Mohammad-Zadeh M, et al. Effect of conjugated linoleic acid supplementation on quality of life in rectal cancer patients undergoing preoperative Chemoradiotherapy. *Pak J Med Sci* 2017;33(2):383-88.

70. Emami H, Nikoobin F, Roayaei M, et al. Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy. *J Res Med Sci* 2014;19(5):445-50.

71. Ahmad IU, Forman JD, Sarkar FH, et al. Soy Isoflavones in Conjunction With Radiation Therapy in Patients With Prostate Cancer. *Nutr Cancer* 2010;62(7):996-1000.

72. Qiu G, Yu Y, Wang Y, et al. The significance of probiotics in preventing radiotherapy-induced diarrhea in patients with cervical cancer: A systematic review and meta-analysis. *Int J Surg* 2019;65:61-69.

73. Wei D, Heus P, van de Wetering FT, et al. Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer. *Cochrane Database Syst Rev* 2018;8:CD008831.

74. Liu MM, Li ST, Shu Y, et al. Probiotics for prevention of radiation-induced diarrhea: A meta-analysis of randomized controlled trials. *PLoS One* 2017;12(6):e0178870.

75. Hamad A, Fragkos KC, Forbes A. A systematic review and meta-analysis of probiotics for the management of radiation induced bowel disease. *Clinical Nutrition* 2013;32(3):353-60.

76. Fuccio L, Guido A, Eusebi LH, et al. Effects of Probiotics for the Prevention and Treatment of Radiation-induced Diarrhea. *J Clin Gastroenterol* 2009;43(6):506-13.

1    **Figure legends**

2
3    **Figure 1** PRISMA flow chart of studies evaluated in the systematic review.
4
5    **Figure 2** Forest plot of effects of biotic, amino acid, PUFA and polyphenol supplements on
6    incidence of diarrhoea.
7
8    **Figure 3** Funnel plot for the meta-analysis that investigated the effect of dietary
9    supplements on incidence of diarrhoea.
10
11   **Figure 4** Forest plot of effect of prebiotic, probiotic and synbiotic supplements on incidence
12   of diarrhoea.
13
14   **Figure 5** Forest plot of effect of dietary supplements on incidence of moderate to severe
15   diarrhoea.
16
17   **Figure 6** Forest plot of effect of dietary supplements on incidence of anti-diarrhoeal
18   medication use.
19
20   **Figure 7** Schematic overview of potential benefits of dietary supplement intervention to
21   alleviate symptoms of gastrointestinal toxicity caused by pelvic radiotherapy.
22
23

1   **Figure 1**

| Study or Subgroup | Dietary supplements Events | Total | Control Events | Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| **1 Biotics Interventions** | | | | | | |
| Castro 2010 | 7 | 20 | 13 | 20 | 4.1% | 0.54 [0.27, 1.06] |
| Chitapanarux 2010 | 3 | 32 | 14 | 31 | 1.9% | 0.21 [0.07, 0.65] |
| De Lorea-Rodriguez 2018 | 5 | 35 | 7 | 35 | 2.2% | 0.71 [0.25, 2.04] |
| Delia 2007 | 77 | 243 | 124 | 239 | 9.3% | 0.61 [0.49, 0.76] |
| Demers 2014 | 49 | 59 | 80 | 89 | 10.3% | 0.92 [0.81, 1.06] |
| Giralt 2008 | 30 | 44 | 24 | 41 | 7.9% | 1.16 [0.84, 1.62] |
| Linn 2019 | 14 | 26 | 23 | 28 | 7.0% | 0.66 [0.44, 0.97] |
| Mansouri-Tehrani 2016 | 7 | 22 | 17 | 24 | 4.2% | 0.45 [0.23, 0.87] |
| Murphy 2000 | 18 | 30 | 25 | 30 | 7.8% | 0.72 [0.52, 1.00] |
| Salminen 1988 | 3 | 11 | 9 | 10 | 2.4% | 0.30 [0.11, 0.81] |
| Sasidharan 2019 | 0 | 50 | 0 | 50 | | Not estimable |
| **Subtotal (95% CI)** | | **572** | | **597** | **57.1%** | **0.66 [0.51, 0.86]** |
| Total events | 213 | | 336 | | | |

Heterogeneity: Tau$^2$ = 0.10; Chi$^2$ = 37.90, df = 9 (P < 0.0001); I$^2$ = 76%
Test for overall effect: Z = 3.11 (P = 0.002)

| Study or Subgroup | Dietary supplements Events | Total | Control Events | Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| **2 Amino Acids Interventions** | | | | | | |
| Kozelsky 2003 | 51 | 64 | 51 | 65 | 9.8% | 1.02 [0.85, 1.21] |
| Kozjek 2011 | 9 | 14 | 10 | 19 | 5.0% | 1.22 [0.69, 2.18] |
| Kucuktulu 2012 | 21 | 23 | 13 | 13 | 9.9% | 0.93 [0.78, 1.10] |
| Manir 2014 | 31 | 42 | 33 | 43 | 9.0% | 0.96 [0.75, 1.23] |
| Vidal-Casariego 2014 | 16 | 32 | 6 | 33 | 3.3% | 2.75 [1.23, 6.14] |
| **Subtotal (95% CI)** | | **175** | | **173** | **37.0%** | **1.05 [0.86, 1.29]** |
| Total events | 128 | | 113 | | | |

Heterogeneity: Tau$^2$ = 0.03; Chi$^2$ = 10.40, df = 4 (P = 0.03); I$^2$ = 62%
Test for overall effect: Z = 0.45 (P = 0.65)

| Study or Subgroup | Dietary supplements Events | Total | Control Events | Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| **3 Poly-unsaturated Fatty Acids Interventions** | | | | | | |
| Aredes 2019 | 5 | 20 | 8 | 20 | 2.7% | 0.63 [0.25, 1.58] |
| **Subtotal (95% CI)** | | **20** | | **20** | **2.7%** | **0.63 [0.25, 1.58]** |
| Total events | 5 | | 8 | | | |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.99 (P = 0.32)

| Study or Subgroup | Dietary supplements Events | Total | Control Events | Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| **4 Polyphenols Interventions** | | | | | | |
| Ahmad 2010 | 1 | 13 | 4 | 13 | 0.7% | 0.25 [0.03, 1.95] |
| Emami 2014 | 4 | 21 | 13 | 21 | 2.6% | 0.31 [0.12, 0.79] |
| **Subtotal (95% CI)** | | **34** | | **34** | **3.3%** | **0.30 [0.13, 0.70]** |
| Total events | 5 | | 17 | | | |

Heterogeneity: Tau$^2$ = 0.00; Chi$^2$ = 0.03, df = 1 (P = 0.86); I$^2$ = 0%
Test for overall effect: Z = 2.78 (P = 0.005)

| | | | | | | |
|---|---|---|---|---|---|---|
| **Total (95% CI)** | | **801** | | **824** | **100.0%** | **0.79 [0.66, 0.94]** |
| Total events | 351 | | 474 | | | |

Heterogeneity: Tau$^2$ = 0.07; Chi$^2$ = 63.28, df = 17 (P < 0.00001); I$^2$ = 73%
Test for overall effect: Z = 2.71 (P = 0.007)
Test for subgroup differences: Chi$^2$ = 13.82, df = 3 (P = 0.003), I$^2$ = 78.3%

1  **Figure 2**

1    **Figure 3**

| Study or Subgroup | Supplement Events | Total | Control Events | Total | Weight | Risk Ratio M–H, Random, 95% CI |
|---|---|---|---|---|---|---|
| **1 Prebiotic Interventions** | | | | | | |
| Murphy 2000 | 18 | 30 | 25 | 30 | 13.3% | 0.72 [0.52, 1.00] |
| Sasidharan 2019 | 0 | 50 | 0 | 50 | | Not estimable |
| **Subtotal (95% CI)** | | **80** | | **80** | **13.3%** | **0.72 [0.52, 1.00]** |
| Total events | 18 | | 25 | | | |
| Heterogeneity: Not applicable | | | | | | |
| Test for overall effect: Z = 1.93 (P = 0.05) | | | | | | |
| | | | | | | |
| **2 Probiotics Interventions** | | | | | | |
| Castro 2010 | 7 | 20 | 13 | 20 | 7.9% | 0.54 [0.27, 1.06] |
| Chitapanarux 2010 | 3 | 32 | 14 | 31 | 4.0% | 0.21 [0.07, 0.65] |
| Delia 2007 | 77 | 243 | 124 | 239 | 15.2% | 0.61 [0.49, 0.76] |
| Demers 2014 | 49 | 59 | 80 | 89 | 16.3% | 0.92 [0.81, 1.06] |
| Giralt 2008 | 30 | 44 | 24 | 41 | 13.5% | 1.16 [0.84, 1.62] |
| Linn 2019 | 14 | 26 | 23 | 28 | 12.2% | 0.66 [0.44, 0.97] |
| **Subtotal (95% CI)** | | **424** | | **448** | **69.1%** | **0.71 [0.52, 0.99]** |
| Total events | 180 | | 278 | | | |
| Heterogeneity: Tau² = 0.11; Chi² = 29.40, df = 5 (P < 0.0001); I² = 83% | | | | | | |
| Test for overall effect: Z = 2.05 (P = 0.04) | | | | | | |
| | | | | | | |
| **3 Synbiotics Interventions** | | | | | | |
| De Lorea-Rodriguez 2018 | 5 | 35 | 7 | 35 | 4.5% | 0.71 [0.25, 2.04] |
| Mansouri-Tehrani 2016 | 7 | 22 | 17 | 24 | 8.1% | 0.45 [0.23, 0.87] |
| Salminen 1988 | 3 | 11 | 9 | 10 | 4.9% | 0.30 [0.11, 0.81] |
| **Subtotal (95% CI)** | | **68** | | **69** | **17.5%** | **0.45 [0.28, 0.73]** |
| Total events | 15 | | 33 | | | |
| Heterogeneity: Tau² = 0.00; Chi² = 1.38, df = 2 (P = 0.50); I² = 0% | | | | | | |
| Test for overall effect: Z = 3.20 (P = 0.001) | | | | | | |
| | | | | | | |
| **Total (95% CI)** | | **572** | | **597** | **100.0%** | **0.66 [0.51, 0.86]** |
| Total events | 213 | | 336 | | | |
| Heterogeneity: Tau² = 0.10; Chi² = 37.90, df = 9 (P < 0.0001); I² = 76% | | | | | | |
| Test for overall effect: Z = 3.11 (P = 0.002) | | | | | | |
| Test for subgroup differences: Chi² = 2.82, df = 2 (P = 0.24), I² = 29.0% | | | | | | |

1    **Figure 4**

| Study or Subgroup | Supplement Events | Total | Control Events | Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| **1 Biotic Interventions** | | | | | | |
| Castro 2010 | 7 | 20 | 13 | 20 | 13.1% | 0.54 [0.27, 1.06] |
| Chitapanarux 2010 | 3 | 32 | 14 | 31 | 7.1% | 0.21 [0.07, 0.65] |
| Mansouri-Tehrani 2016 | 7 | 22 | 17 | 24 | 13.4% | 0.45 [0.23, 0.87] |
| Murphy 2000 | 13 | 30 | 23 | 30 | 17.6% | 0.57 [0.36, 0.89] |
| **Subtotal (95% CI)** | | **104** | | **105** | **51.2%** | **0.49 [0.36, 0.67]** |
| Total events | 30 | | 67 | | | |

Heterogeneity: Tau² = 0.00; Chi² = 2.92, df = 3 (P = 0.40); I² = 0%
Test for overall effect: Z = 4.41 (P < 0.0001)

| | | | | | | |
|---|---|---|---|---|---|---|
| **2 Amino Acid Interventions** | | | | | | |
| Kozelsky 2003 | 35 | 64 | 33 | 65 | 20.4% | 1.08 [0.78, 1.49] |
| Kozjek 2011 | 5 | 14 | 7 | 19 | 9.5% | 0.97 [0.39, 2.42] |
| Manir 2014 | 23 | 42 | 23 | 43 | 19.0% | 1.02 [0.69, 1.51] |
| **Subtotal (95% CI)** | | **120** | | **127** | **48.8%** | **1.05 [0.82, 1.34]** |
| Total events | 63 | | 63 | | | |

Heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 2 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.70)

| | | | | | | |
|---|---|---|---|---|---|---|
| **Total (95% CI)** | | **224** | | **232** | **100.0%** | **0.68 [0.48, 0.98]** |
| Total events | 93 | | 130 | | | |

Heterogeneity: Tau² = 0.14; Chi² = 17.15, df = 6 (P = 0.009); I² = 65%
Test for overall effect: Z = 2.08 (P = 0.04)
Test for subgroup differences: Chi² = 13.91, df = 1 (P = 0.0002), I² = 92.8%

1    **Figure 5**

|  | Supplement | | Control | | | Risk Ratio | Risk Ratio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M–H, Random, 95% CI | M–H, Random, 95% CI |
|---|---|---|---|---|---|---|---|
| **1 Biotic Interventions** | | | | | | | |
| Castro 2010 | 3 | 20 | 7 | 20 | 6.7% | 0.43 [0.13, 1.43] | |
| Chitapanarux 2010 | 3 | 32 | 10 | 31 | 6.8% | 0.29 [0.09, 0.96] | |
| Giralt 2008 | 16 | 44 | 12 | 41 | 15.0% | 1.24 [0.67, 2.30] | |
| Linn 2019 | 13 | 26 | 24 | 28 | 19.8% | 0.58 [0.39, 0.88] | |
| Mansouri–Tehrani 2016 | 2 | 22 | 9 | 24 | 5.2% | 0.24 [0.06, 1.00] | |
| Urbancsek 2001 | 36 | 102 | 49 | 103 | 21.9% | 0.74 [0.53, 1.03] | |
| **Subtotal (95% CI)** | | **246** | | **247** | **75.3%** | **0.64 [0.44, 0.92]** | |
| Total events | 73 | | 111 | | | | |

Heterogeneity: Tau$^2$ = 0.08; Chi$^2$ = 9.07, df = 5 (P = 0.11); I$^2$ = 45%
Test for overall effect: Z = 2.38 (P = 0.02)

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **2 Amino Acid Interventions** | | | | | | | |
| Kozelsky 2003 | 39 | 64 | 39 | 65 | 23.1% | 1.02 [0.77, 1.34] | |
| Kucuktulu 2012 | 0 | 23 | 5 | 13 | 1.5% | 0.05 [0.00, 0.89] | |
| **Subtotal (95% CI)** | | **87** | | **78** | **24.7%** | **0.31 [0.01, 6.88]** | |
| Total events | 39 | | 44 | | | | |

Heterogeneity: Tau$^2$ = 4.15; Chi$^2$ = 4.98, df = 1 (P = 0.03); I$^2$ = 80%
Test for overall effect: Z = 0.74 (P = 0.46)

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Total (95% CI)** | | **333** | | **325** | **100.0%** | **0.67 [0.47, 0.96]** | |
| Total events | 112 | | 155 | | | | |

Heterogeneity: Tau$^2$ = 0.12; Chi$^2$ = 18.23, df = 7 (P = 0.01); I$^2$ = 62%
Test for overall effect: Z = 2.16 (P = 0.03)
Test for subgroup differences: Chi$^2$ = 0.21, df = 1 (P = 0.65), I$^2$ = 0%

1    **Figure 6**
2

1  **Figure 7**
2

1    **Table 1 Characteristics of included studies**

| Study | Cancer type | Intervention | Sample size |
|---|---|---|---|
| **Biotics** | | | |
| Sasidharan, 2019[52] | Cervical | Prebiotic: resistant starch | 100 |
| Linn, 2019[53] | Cervical | Synbiotic: *L. acidophilus, B. animalis* and yoghurt | 54 |
| De Lorea-Rodriguez, 2018[54] | Cervical | Synbiotic: *L. acidophilus, B. lactis* and insulin | 70 |
| Mansouri-Tehrani, 2016[55] | Pelvic | Synbiotic: *S. thermophiles, Lactobacilli, Bifidobacter* and honey | 46 |
| Garcia-Peris, 2016[56] | Gynaecological | Prebiotic: insulin oligosaccharide and fructo-oligosaccharide | 38 |
| Itoh, 2015[57] | Cervical | Prebiotic: hydrolysed rice bran | 20 |
| Demers, 2014[58] | Gynaecological, rectal or prostate | Probiotic: *L. acidophilus* and *B. longum* | 148 |
| Chitapanarux, 2010[59] | Cervical | Probiotic: *L. acidphilus* and *B. bifidum* | 63 |
| Castro, 2010[60] | Endometrial | Probiotic: *L. casei* and *B. breve* | 40 |
| Giralt, 2008[30] | Cervical or endometrial | Synbiotic: *L. casei, S. thermophiles* and *L. delbrueckii* | 85 |
| Delia, 2007[34] | Cervical or rectal | Probiotic: three strains of *bifidobacteria* and one strain of *streptococcu*s | 482 |
| Urbancsek, 2001[61] | Pelvic | Probiotic: *L. rhamnosus* | 205 |
| Murphy, 2000[62] | Gynaecological | Prebiotic: psyllium | 60 |
| Salminen, 1988[63] | Gynaecological | Synbiotics: *L. acidphilus* and lactulose | 21 |
| | | | |
| **Amino acids** | | | |
| Vidal-Casariego, 2014[64] | Pelvic | Glutamine | 65 |
| Manir, 2014[65] | Pelvic | Glutamine | 85 |
| Kucuktulu, 2012[66] | Rectal, bladder, prostate or gynaecological | Glutamine | 36 |
| Kozjek, 2011[67] | Rectal cancer | Glutamine | 33 |
| Kozelsky, 2003[68] | Gynaecological, rectal or prostate | Glutamine | 129 |
| | | | |
| **PUFAs** | | | |
| Aredes, 2019[36] | Pelvic | EPA and DHA | 42 |
| Faramarzi, 2017[69] | Rectal | CLA | 26 |
| | | | |
| **Polyphenols** | | | |
| Emami, 2014[70] | Pelvic | Green tea | 40 |
| Ahmad, 2010[71] | Prostate | Soy isoflavones | 31 |

2    All studies are RCTs

1    **Table 2 Meta-analyses of other gastrointestinal outcomes**

| Outcome | Number of studies | Number of participants | Risk ratio (95% CI) | Test for overall effect, P | Heterogeneity $I^2$ (%; P value) |
|---|---|---|---|---|---|
| Incidence of vomiting | 4 | 237 | 0.99 (0.79, 1.25) | 0.95 | 59 (0.52) |
| Incidence of nausea | 3 | 192 | 0.74 (0.36, 1.50) | 0.40 | 0 (0.08) |
| Incidence of flatulence/bloating | 3 | 152 | 1.12 (0.59, 2.12) | 0.72 | 76 (0.01) |
| The mean number of bowel movements per day* | 3 | 1045 | -3.88 (-10.29, 2.52) | 0.23 | 99 (<0.01) |

2    *The outcome was mean difference.